Mirae Asset Global Etfs Holdings Ltd. Uro Gen Pharma Ltd. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $43.4 Billion
- Q1 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 23,320 shares of URGN stock, worth $115,434. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,320
Previous 21,667
7.63%
Holding current value
$115,434
Previous $230,000
11.74%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding URGN
# of Institutions
142Shares Held
41.6MCall Options Held
91.4KPut Options Held
42.1K-
Ubs Asset Management Americas Inc Chicago, IL4.36MShares$21.6 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY3.83MShares$19 Million0.69% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.21MShares$15.9 Million0.74% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$11.4 Million0.17% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$10.9 Million0.0% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $113M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...